Phase 1 Human Metapneumovirus Clinical Trials

2 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–2 of 2 trials

Recruiting

Phase 1

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Respiratory Syncytial Virus VaccinationHuman Metapneumovirus VaccinationParainfluenza Vaccination

Clover Biopharmaceuticals AUS Pty192 enrolled1 locationNCT06984094

Recruiting

Phase 1

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

Human MetapneumovirusHuman Parainfluenza Virus Type 3

National Institute of Allergy and Infectious Diseases (NIAID)25 enrolled4 locationsNCT06546423